ArticleFASEB bioAdvances2026
Age and Sex Impact the Role of Thrombospondin-2 and Thrombospondin-5 in Response to Hindlimb Ischemia.
Article in FASEB bioAdvances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Surgical Rodent Models for the Study of Peripheral Arterial Disease.Biomedicines · 2026Review
- Age and Sex Impact the Role of Thrombospondin-2 and Thrombospondin-5 in Response to Hindlimb Ischemia.FASEB bioAdvances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Peripheral arterial disease progression to critical limb ischemia remains a significant burden in the aged, necessitating revascularization. Therapies to enhance neovascularization, such as angiogenesis or arteriogenesis, may provide an option for patients not suitable for surgery. The thrombospondins (TSPs) are secreted matricellular glycoproteins, with TSP-1, TSP-2, and TSP-5 implicated in neovascularization. Currently, there is little data regarding the effects of TSP-2, TSP-5, sex, and aging on angiogenesis and arteriogenesis. In vitro, the effect of TSP-2 or TSP-5 on early or late passage endothelial cell (EC) tubule formation or disruption was assessed. In vivo, angiogenesis, and arteriogenesis in male and female, young (14-16 weeks) and old (105-110 weeks) wild-type, TSP-2 and TSP-5 knockout mice were compared. To assess the effect of sex hormones, neovascularization was assessed in ovariectomized young female mice. After 14 days, angiogenesis and arteriogenesis were quantified using immunohistochemistry. Laser Doppler was used to confirm > 50% decrease in blood flow. In vitro: TSP-2 inhibited angiogenesis in early passage ECs and disrupted tubules in late passage ECs. TSP-5 prevented early passage tubule disruption. Late passage cells showed greater disruption than early passage. In vivo: TSP-2 was anti-angiogenic in young mice and anti-arteriogenic in old mice; TSP-5 had no effect on angiogenesis but largely negatively impacted arteriogenesis. Females showed reduced angiogenesis/arteriogenesis versus males, aging blunted both responses, and TSP-2/TSP-5 knockouts altered sex- and age-specific ischemic responses. In conclusion, we broadly elucidate the differential effects of TSP-2, TSP-5, sex and aging on neovascularization after inducing limb ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.